Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
UNLIMITED Watchlists, Portfolios, Screeners, and other Barchart tools with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Immutep Ltd ADR (IMMP)

Immutep Ltd ADR (IMMP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 434,747
  • Shares Outstanding, K 147,372
  • Annual Sales, $ 6,690 K
  • Annual Income, $ -39,780 K
  • EBIT $ 0 M
  • EBITDA $ -37 M
  • 60-Month Beta 1.92
  • Price/Sales 60.79
  • Price/Cash Flow N/A
  • Price/Book 4.36

Options Overview Details

View History
  • Implied Volatility 196.89% (+74.51%)
  • Historical Volatility 91.90%
  • IV Percentile 52%
  • IV Rank 19.29%
  • IV High 758.44% on 11/14/25
  • IV Low 62.69% on 10/03/25
  • Expected Move (DTE 22) 0.76 (24.56%)
  • Put/Call Vol Ratio 11.00
  • Today's Volume 132
  • Volume Avg (30-Day) 399
  • Put/Call OI Ratio 0.07
  • Today's Open Interest 4,255
  • Open Int (30-Day) 5,368
  • Expected Range 2.32 to 3.84

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 3 analysts offering recommendations.
Earnings Estimates - Current Qtr 09/30/25
See More
  • Average Estimate N/A
  • Number of Estimates 0
  • High Estimate N/A
  • Low Estimate N/A
  • Prior Year N/A
  • Growth Rate Est. (year over year) unch

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.67 +84.43%
on 12/03/25
3.53 -12.75%
on 12/08/25
+1.32 (+75.00%)
since 11/24/25
3-Month
1.64 +87.80%
on 09/25/25
3.53 -12.75%
on 12/08/25
+1.39 (+82.25%)
since 09/24/25
52-Week
1.32 +133.33%
on 04/07/25
3.53 -12.75%
on 12/08/25
+1.13 (+57.95%)
since 12/24/24

Most Recent Stories

More News
Immutep Completes FDA Project Optimus, Advances Efti Trials

Elevate Your Investing Strategy: Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence. Immutep (...

IMMP : 3.08 (+4.41%)
Immutep Announces Favorable Safety Profile for First-in-Class LAG-3 Agonist IMP761 in Phase I Trial

Immutep reports no adverse events in Phase I trial of IMP761, a LAG-3 agonist for autoimmune diseases, with more data expected in 2025.Quiver AI SummaryImmutep Limited has released promising initial safety...

IMMP : 3.08 (+4.41%)
Immutep Reports Promising Clinical Results for Efti in Combination with Pembrolizumab in Patients with Difficult-to-Treat Head and Neck Cancer

Immutep reports promising clinical results for efti combined with pembrolizumab in treating difficult head and neck cancer patients.Quiver AI SummaryImmutep Limited has announced promising clinical results...

IMMP : 3.08 (+4.41%)
Why Did Immutep Ltd Stock Soar Recently?

Analysts and investors alike appear enamored with Immutep Ltd, whose earnings are growing; more of which could come from their latest product candidate.

MKGAY : 38.3600 (-0.62%)
IMMP : 3.08 (+4.41%)
PFE : 25.03 (+0.60%)
Immutep Reports New Positive Interim Data from its Phase II Study of LAG-3 Candidate, Eftilagimod Alpha, in 2nd Line PD-X Refractory NSCLC

Encouraging efficacy results continue for patients with 2nd line PD-X refractory non-small cell lung cancer (NSCLC)Patients in this 2nd line setting had...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)
Immutep Granted Japanese Patent for IMP761, A First-In-Class Immunosuppressive Antibody Targeting Lag-3

SYDNEY, AUSTRALIA, July 06, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)
Immutep Reports Positive Overall Response Rate in its Phase II Clinical Trial in 1st line NSCLC for PD-L1 All-Comers

TACTI-002 has met its primary objective for 1st line non-small cell lung cancer (NSCLC) patients in a PD-L1 all-comer Phase II clinical trial conducted in...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)
Immutep Global Webcast to Discuss TACTI-002 Data Presented at ASCO 2022

SYDNEY, AUSTRALIA, June 02, 2022 (GLOBE NEWSWIRE) -- Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)
Immutep Announces Publication of TACTI-002 and TACTI-003 Abstracts at ASCO 2022

Efti in combination with pembrolizumab continues to show favourable antitumor activity in 1st line non-small cell lung cancer (NSCLC) patients from...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)
Immutep to Present at Investor Conferences

SYDNEY, AUSTRALIA, May 20, 2022 (GLOBE NEWSWIRE) --  Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep” or “the Company”), a biotechnology company...

IMMP : 3.08 (+4.41%)
IMM.AX : 0.415 (unch)

Business Summary

Immutep Limited is a biotechnology company. It engaged in developing novel immunotherapy treatments for cancer and autoimmune disease. The company's product pipeline consists of eftilagimod alpha, IMP731, IMP701 and IMP761 which are in clinical stage. It operates primarily in Europe, Australia and the...

See More

Key Turning Points

3rd Resistance Point 3.62
2nd Resistance Point 3.42
1st Resistance Point 3.25
Last Price 3.08
1st Support Level 2.88
2nd Support Level 2.68
3rd Support Level 2.51

See More

52-Week High 3.53
Last Price 3.08
Fibonacci 61.8% 2.69
Fibonacci 50% 2.42
Fibonacci 38.2% 2.16
52-Week Low 1.32

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar